Neovasc Inc (US) (NVCN) Earns Coverage Optimism Rating of 0.24
Media coverage about Neovasc Inc (US) (NASDAQ:NVCN) (TSE:NVC) has trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Neovasc Inc (US) earned a news sentiment score of 0.24 on Accern’s scale. Accern also assigned media coverage about the medical equipment provider an impact score of 45.9140264862528 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news headlines that may have impacted Accern’s scoring:
- Look closely Shares of Neovasc Inc. (NVCN) – usstockjournal (usstockjournal.com)
- Neovasc Inc. (NVCN) projected to achieve 79.70% earnings growth for this year – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Signals from Technical Perspective: Neovasc Inc (NASDAQ: NVCN) – Alpha Beta Stock (alphabetastock.com)
- Neovasc Inc (US) (NVCN) Short Interest Down 37.2% in February (americanbankingnews.com)
- Gagnon Advisors LLC Acquires 610,376 Shares of Neovasc Inc (US) (NVCN) (americanbankingnews.com)
A number of equities analysts have recently commented on NVCN shares. ValuEngine lowered shares of Neovasc Inc (US) from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Canaccord Genuity restated a “buy” rating and issued a $1.05 price objective on shares of Neovasc Inc (US) in a research report on Friday, January 19th. Finally, Zacks Investment Research lowered shares of Neovasc Inc (US) from a “hold” rating to a “sell” rating in a research report on Wednesday, January 31st. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. Neovasc Inc (US) has a consensus rating of “Hold” and an average target price of $2.95.
About Neovasc Inc (US)
Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.
Receive News & Ratings for Neovasc Inc (US) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc Inc (US) and related companies with MarketBeat.com's FREE daily email newsletter.